A Revolutionary Breakthrough In Skin Cancer Detection

VITA IMAGING

Vita Imaging

Vita Imaging, Inc. is a medical device company committed to commercializing innovative systems for the detection of cancer. The company has licensed a revolutionary, patent-protected, platform technology from the British Columbia Cancer Agency (BCCA). Using this technology, Vita Imaging has developed AURA, an award-winning device for the detection of skin cancer. AURA previously achieved market clearance in Canada, the European Union, and Australia. FDA Class 3 approval is pending.

Vita Imaging plans to expand its core technology of skin cancer detection to develop CORE aimed at the detection of internal organ cancers including lung, colon, and oral cancer. A clinical study using CORE to detect lung cancer has been published in a peer reviewed publication.

AURA

Vita Imaging's AURA is a patent protected, safe, non-invasive imaging and spectroscopy system designed to aid physicians and healthcare professionals in the early detection of skin cancer by determining malignant from benign skin lesions. AURA provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells in less than one second. AURA provides rapid, real time results, faster than other skin cancer detection devices in the market.

Vita Imaging Inc.,
5390 Hellyer Avenue
San Jose, CA 95138

Contact: Thinh Tran, CEO
Phone: +1 408-460-9457

Website: www.vita-imaging.com
PW: DefyCancer

Early Detection Saves Lives

Jointly developed by the British Columbia Cancer Agency (BCCA) and the University of British Columbia (UBC) with clinical testing conducted at Vancouver General Hospital, AURA was used in a Patient Study spanning six years with over 800 patients including the assessment of over 1,000 lesions. To date, it is the most comprehensive Raman based skin cancer study conducted globally. Results, published in peer-reviewed publications, showed sensitivity of 90% with 82.1% specificity, and sensitivity of 99% with specificity of 44.5% in identifying patients with Melanoma. These performance results are superior to other devices in the market.

AURA helps automate the current process of diagnosis by allowing rapid scanning of suspicious skin lesions in at risk individuals and maximizes efficiencies in the workflow by optimizing clinical impact through improved patient outcomes and reduced wait times.

Product development of AURA is led by well-respected, award-winning pioneers in the field of cancer imaging. The multi-disciplinary scientific, medical, and technical team is comprised of world renowned experts in cancer detection.

The Facts on Skin Cancer

"Cancer causes about 1 in every 6 deaths worldwide, more than AIDS, tuberculosis, and malaria combined."

-The American Cancer Society

- Skin cancer is the most common form of cancer in the United States
- 1 out of 3 new cancers diagnosed worldwide will be skin cancer
- 1 out of 5 Americans will develop skin cancer in their lifetime
- Every hour, one person in the United States dies of melanoma
- 50% of people over the age of 65 in the US will be affected by skin cancer
- Between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year
- Survival rate of patients where the disease is detected early is 99%
- 5-Year survival rate of patients with advanced, Stage 4 Melanoma is 30 %
- Annual cost of treating skin cancer in the United States is estimated at $8 billion USD